RNAi-based validation of antibodies for reverse phase protein arrays
2010

Using RNAi to Validate Antibodies for Protein Detection

Sample size: 10 publication 15 minutes Evidence: moderate

Author Information

Author(s): Heiko A. Mannsperger, Stefan Uhlmann, Christian Schmidt, Stefan Wiemann, Özgür Sahin, Ulrike Korf

Primary Institution: German Cancer Research Center, Division of Molecular Genome Analysis, Heidelberg, Germany

Hypothesis

Can RNA interference (RNAi) be used to validate the specificity and sensitivity of antibodies for reverse phase protein arrays (RPPA)?

Conclusion

RNAi is an effective method for identifying specific and sensitive antibodies suitable for RPPA applications.

Supporting Evidence

  • RNAi was shown to effectively reduce target protein levels in cell lines.
  • The study compared multiple antibodies to assess their specificity and sensitivity.
  • Results indicated that some antibodies performed better in RPPA than in Western blot.

Takeaway

This study shows that scientists can use a special technique called RNAi to check if antibodies work well for detecting proteins in experiments.

Methodology

The study used RNA interference to knock down target proteins and assessed antibody performance through reverse phase protein arrays and Western blotting.

Potential Biases

Potential bias in antibody selection and performance evaluation based on supplier claims.

Limitations

The study primarily focused on commercially available antibodies, which may not represent all antibody types.

Participant Demographics

The study used human breast cancer cell line MDA-MB-231 for experiments.

Digital Object Identifier (DOI)

10.1186/1477-5956-8-69

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication